Search results for " protocols"

Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

2006

Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice

1990

The antimetastatic activity of adriamycin in combination with proteinase inhibitors was investigated in mice bearing the metastatic tumors L1210 leukemia, Lewis lung carcinoma or M5076 sarcoma. Leupeptin, a cathepsin B inhibitor, when administered as a single agent was devoid of antimetastatic activity but some therapeutic activity was noted in mice with Lewis lung carcinoma when the agent was administered in combination with adriamysin. Pepstatin A, a cathepsin D inhibitor, had no effect as a single agent in mice with L1210 leukemia but displayed some antimetastatic activity in mice with Lewis lung carcinoma. In mice with M5076 sarcoma the combination of pepstatin A and adriamycin resulted…

Energy-Efficient Protocol Design

2015

Recent studies have shown that the total energy consumed by the Internet has followed an increasing trend over the years. A considerable part of this energy is wasted due to an inefficient utilization of edge devices , that is, Personal Computers (PCs) and other user equipment in homes and offices. PCs are often left on even when they are not used (e.g., overnight or during weekends), while other edge devices, such as printers, IP phones, and displays, are typically kept always on , especially in public buildings. A number of solutions have been proposed for eliminating, or reducing, energy wastes caused by edge devices. In this chapter, we propose a general taxonomy for their classificatio…

Understanding 802.11e contention-based prioritization mechanisms and their coexistence with legacy 802.11 stations

2005

The IEEE 802.11e task group has reached a stable consensus on two basic contention-based priority mechanisms to promote for standardization: usage of different arbitration interframe spaces and usage of different minimum/maximum contention windows. The goal of this article is to provide a thorough understanding of the principles behind their operation. To this purpose, rather than limit our investigation to high-level (e.g. throughput and delay) performance figures, we take a closer look at their detailed operation, also in terms of low-level performance metrics (e.g., the probability of accessing specific channel slots). Our investigation on one hand confirms that AIFS differentiation prov…

Polypoid anal melanoma. A case report and review of the literature

2016

Ano-rectal melanoma is an uncommon finding in patients complaining of rectal bleeding and/or anal mass often misinterpreted as a haemorroidal pile.A 55-years-old woman, complaining of rectal bleeding, frequent anal pain and anal mass suspected for haemorroidal thrombosis was referred for evaluation and possible treatment. A brown polypoid mass arising from the anal canal/lower rectum with a maximum diameter of 6 cm was diagnosed. The hystological examination of the neoplasm, transanally removed, revealed the presence of a polypoid melanoma partially involving the resection margin. Nor metastases nor limph-node involvement were found at the total-body CT scan and at a CT-PET. C-KIT examinati…

Cytotoxicity of apigenin toward multiple myeloma cell lines and suppression of iNOS and COX-2 expression in STAT1-transfected HEK293 cells.

2020

Apigenin is one of the most abundant dietary flavonoids that possesses multiple bio-functions.This study was designed to determine the influence of apigenin on gene expressions, cancer cells, as well as STAT1/COX-2/iNOS pathway mediated inflammation and tumorigenesis in HEK293-STAT1 cells. Furthermore, the cytotoxic activity toward multiple myeloma (MM) cell lines was investigated.Bioinformatic analyses were used to predict the sensitivity and resistance of tumor cells toward apigenin and to determine cellular pathways influenced by this compound. The cytotoxic and ferroptotic activity of apigenin was examined by the resazurin reduction assay. Additionally, we evaluated apoptosis, and cell …

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Performance Analysis of Synchronous Duty-Cycled MAC Protocols

2015

In this letter, we propose an analytical model to evaluate the performance of the S-MAC protocol. The proposed model improves the accuracy of previous models in two aspects. First, it incorporates the dependence among the nodes within a cluster by defining a DTMC that models the number of active nodes, whereas the previous models considered that nodes were mutually independent. Second, it proposes new methods for calculating packet delay and energy consumption. The analytical model is validated through discrete-event based simulations. Numerical results demonstrate that the proposed analytical model and methods yield accurate results under realistic assumptions

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and…

2003

Abstract Purpose: we carried out a phase III randomized trial to compare vinorelbine–cisplatin regimen to gemcitabine–cisplatin regimen, and to a sequential administration of gemcitabine–ifosfamide followed by vinorelbine–cisplatin or the opposite sequence of vinorelbine–cisplatin followed by ifosfamide–gemcitabine according to the ‘worst drug rule’ hypothesis in patients with locally advanced unresectable stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoint was survival parameters, while secondary endpoints included analysis of response rates and toxicity. Patients and methods: patients were randomized to receive: (a) gemcitabine 1000 mg/m2 on days 1, 8 and 15…

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…